MX2022011523A - Terapia combinada para leucemia mielógena aguda. - Google Patents

Terapia combinada para leucemia mielógena aguda.

Info

Publication number
MX2022011523A
MX2022011523A MX2022011523A MX2022011523A MX2022011523A MX 2022011523 A MX2022011523 A MX 2022011523A MX 2022011523 A MX2022011523 A MX 2022011523A MX 2022011523 A MX2022011523 A MX 2022011523A MX 2022011523 A MX2022011523 A MX 2022011523A
Authority
MX
Mexico
Prior art keywords
combination therapy
myeloid leukemia
acute myeloid
difluoroacetamide
dioxopiperidin
Prior art date
Application number
MX2022011523A
Other languages
English (en)
Inventor
Michael Pourdehnad
Jinhong Fan
Emily Pace
Daniel W Pierce
Tonia J Buchholz
Tsun-Wen Yao
Nian Gong
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2022011523A publication Critical patent/MX2022011523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos de tratamiento de la LMA que comprenden administrar 2-(4-clorofenil)-N-((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroaceta mida o un estereoisómero o mezcla de estereoisómeros, sal farmacéuticamente aceptable, tautómero, profármaco, solvato, hidrato, cocristal, clatrato o polimorfo de esta en una terapia combinada.
MX2022011523A 2020-03-16 2021-03-12 Terapia combinada para leucemia mielógena aguda. MX2022011523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990372P 2020-03-16 2020-03-16
PCT/US2021/022182 WO2021188387A1 (en) 2020-03-16 2021-03-12 Combination therapy for acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2022011523A true MX2022011523A (es) 2022-12-13

Family

ID=77772140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011523A MX2022011523A (es) 2020-03-16 2021-03-12 Terapia combinada para leucemia mielógena aguda.

Country Status (11)

Country Link
US (1) US20230149379A1 (es)
EP (1) EP4121051A4 (es)
JP (1) JP2023520177A (es)
KR (1) KR20220154175A (es)
CN (1) CN115515582A (es)
AU (1) AU2021239822A1 (es)
BR (1) BR112022018515A2 (es)
CA (1) CA3171588A1 (es)
IL (1) IL296557A (es)
MX (1) MX2022011523A (es)
WO (1) WO2021188387A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020379680A1 (en) 2019-11-05 2022-05-26 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
AU2020396543A1 (en) 2019-12-06 2022-06-16 Celgene Corporation Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
WO2023154904A2 (en) * 2022-02-11 2023-08-17 Loma Linda University Compositions and methods for treating acute myeloid leukemia
WO2024091959A1 (en) * 2022-10-24 2024-05-02 The Regents Of The University Of California Drug resistant immune cells
WO2024211523A1 (en) * 2023-04-06 2024-10-10 Abbvie Inc. Dosing regimens for use in preventing relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation with venetoclax in combination with azacitidine
WO2025122985A1 (en) * 2023-12-08 2025-06-12 Hibercell, Inc. Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120446A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP7163281B2 (ja) * 2016-06-06 2022-10-31 セルジーン コーポレイション ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドによる血液系悪性腫瘍の治療
EP3644999B1 (en) * 2017-06-30 2022-12-14 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide

Also Published As

Publication number Publication date
AU2021239822A1 (en) 2022-10-13
EP4121051A1 (en) 2023-01-25
IL296557A (en) 2022-11-01
CA3171588A1 (en) 2021-09-23
WO2021188387A1 (en) 2021-09-23
EP4121051A4 (en) 2024-04-17
BR112022018515A2 (pt) 2022-11-16
KR20220154175A (ko) 2022-11-21
US20230149379A1 (en) 2023-05-18
CN115515582A (zh) 2022-12-23
JP2023520177A (ja) 2023-05-16

Similar Documents

Publication Publication Date Title
MX2022011523A (es) Terapia combinada para leucemia mielógena aguda.
MX388717B (es) Tratamiento de una neoplasia maligna hematologica con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida.
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
MX2022001410A (es) Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamid a.
MX2025002170A (es) Inhibidores de kras g12c
ZA202400988B (en) Aak1 inhibitor and use thereof
EP4275707A3 (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
MX2021007800A (es) Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
MX2024014203A (es) Compuesto de bencimidazol o azabencimidazol, metodo de preparacion para el mismo y su uso
FI3908281T3 (fi) Antiproliferatiivisia yhdisteitä ja toisia aktiivisia aineita käytettäväksi multippelin myelooman hoidossa
ZA202500422B (en) Nitrogen-containing compound and use thereof
ZA202311035B (en) Phosphonyl derivative, and composition and pharmaceutical application thereof
MX388643B (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
NZ790364A (en) Compounds and compositions for use in treating skin disorders
PH12021551985A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
MX2023014630A (es) Activadores de dimetoxifenilalquilamina de receptores de serotonina.
PH12014501495A1 (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
MX2024002409A (es) Terapias contra el cancer.
MX392359B (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas
EA201892687A1 (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
MX2023013011A (es) Métodos de tratamiento con n-((r)-1-(3-cloropiridin-2-il)- 2,2,2-trifluoroetil)-2-((s)-2,6-dioxopiperidin-3-il)-1- oxoisoindolin-5-carboxamida.